Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health services entities : Aptinyx inc. save search
Chemotherapy Induced Peripheral Neuropathy Treatment Market Projected Strong Growth to $2.25 Billion by 2028 Amid Advancements in Cancer Treatment
Published: 2024-03-07 (Crawled : 00:00) - prnewswire.com
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: 1.41%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
QDEL | $41.43 -1.76% -1.79% 550K
|
Health Technology
|
| O: 1.14%
H: 4.36%
C: 3.16%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.1%
H: 0.18%
C: -1.25%
cancer treatment growth market
Mucopolysaccharidosis Market to Accelerate Substantially, Predicts DelveInsight | Key Companies Working in the Market - Ultragenyx, Abeona, Homology, Denali, LYSOGENE, Allievex, Bellicum, Shire, Takeda
Published: 2023-08-01 (Crawled : 21:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -2.23%
H: 0.0%
C: -0.56%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
SEEL | $0.4263 -7.75% -8.4% 290K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.27%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -2.64%
H: 0.0%
C: 0.0%
RGNX | $18.04 -0.28% -0.28% 350K
|
Health Technology
|
| O: -0.52%
H: 1.65%
C: -0.79%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -1.2%
H: 3.25%
C: 3.25%
DNLI | $17.85 -2.25% -2.3% 990K
|
Health Technology
|
| O: -1.2%
H: 0.0%
C: -1.5%
companies market
Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon
Published: 2023-07-26 (Crawled : 21:00) - prnewswire.com
COYA | $8.3 -7.98% -8.67% 75K
|
|
| O: 0.0%
H: 1.87%
C: 0.5%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.06%
H: 1.18%
C: 0.37%
SEEL | $0.4263 -7.75% -8.4% 290K
|
Health Technology
|
| O: 1.48%
H: 0.73%
C: -2.19%
PRTA 4 | $21.99 -1.12% -1.14% 530K
|
Health Technology
|
| O: 1.08%
H: 2.08%
C: 1.79%
PASG | $1.24 -7.46% -8.06% 98K
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: -8.82%
IONS | $41.56 -0.43% -0.43% 760K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.56%
DNLI | $17.85 -2.25% -2.3% 990K
|
Health Technology
|
| O: 1.22%
H: 0.0%
C: -1.42%
SAVA | $20.015 -12.02% -13.66% 2.1M
|
Health Technology
|
| O: 0.6%
H: 1.74%
C: 1.24%
BIVI | $0.537 5.19% 4.93% 1.8M
|
Health Technology
|
| O: 0.43%
H: 0.85%
C: -2.12%
AXSM | $68.26 -1.29% -1.3% 430K
|
Health Technology
|
| O: 0.56%
H: 3.6%
C: 0.99%
companies active dementia market
Delisting of Securities of Puhui Wealth Investment Management Co., Ltd.; National Energy Services Reunited Corp.; Bed Bath & Beyond Inc.; IMV Inc.; Celyad Oncology SA; Aptinyx Inc.; Athenex, Inc.; Greencity Acquisition Corporation; QualTek Services Inc.; Bellicum Pharmaceuticals, Inc.; Wejo Group Limited; Cyxtera Technologies, Inc.; HTG Molecular Diagnostics, Inc.; Unico American Corporation; PolarityTE, Inc.; Oncorus, Inc.; and OncoSec Medical Incorporated from The Nasdaq Stock Market
Published: 2023-07-06 (Crawled : 20:00) - globenewswire.com
ONCSQ | $0.0001 43900.0% 820
|
Manufacturing
|
| O: -15.79%
H: 12.5%
C: -6.25%
CYXTQ | $0.0007 -57.14% 1.8K
|
|
| O: -4.89%
H: 17.73%
C: -5.28%
QTEKQ | $0.012 125.0% 640K
|
Construction
|
| O: -17.88%
H: 11.07%
C: -0.37%
ATNXQ | $0.0152 -85.53% 3.6K
|
Manufacturing
|
| O: 54.31%
H: 0.0%
C: -29.37%
IMVIQ | $0.0001 36400.0% 6K
|
Manufacturing
|
| O: -18.75%
H: 192.31%
C: 32.62%
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -2.05%
H: 29.3%
C: 0.0%
NESR | $8.8 0.0% 7.7K
|
Industrial Services
|
| O: 0.0%
H: 0.0%
C: 0.0%
NDAQ | $60.2 -2.15% -2.19% 3.2M
|
Finance
|
| O: -0.22%
H: 0.8%
C: 0.18%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -14.11%
H: 7.11%
C: 6.2%
management nasdaq energy services beyond group acquisition medical molecular market
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published: 2023-04-19 (Crawled : 15:00) - prnewswire.com
NVO | $123.9 -0.49% 0.23% 2.9M
|
Health Technology
|
| O: -3.51%
H: 1.28%
C: 0.74%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.17%
H: 0.2%
C: -0.02%
VTGN | $4.78 -2.25% -2.3% 270K
|
Health Technology
|
| O: 0.0%
H: 2.59%
C: -0.49%
DNLI | $17.85 -2.25% -2.3% 990K
|
Health Technology
|
| O: -1.11%
H: 1.31%
C: 0.56%
BIVI | $0.537 5.19% 4.93% 1.8M
|
Health Technology
|
| O: -0.24%
H: 4.29%
C: 0.49%
BIIB | $196.76 -0.72% -0.72% 1.2M
|
Health Technology
|
| O: -0.39%
H: 0.4%
C: -0.14%
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.05%
H: 13.81%
C: 11.81%
AVXL | $4.23 -1.51% -1.54% 1.1M
|
Health Technology
|
| O: -0.74%
H: 2.73%
C: 1.61%
disease companies parkinson's pipeline space trial
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
Published: 2023-03-30 (Crawled : 22:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -0.66%
H: 0.0%
C: 0.0%
year review results
Aptinyx to Present at the SVB Securities Global Biopharma Conference
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
| Email alert
Add to watchlist
biopharma global conference
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires
Published: 2022-11-16 (Crawled : 23:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: -2.06%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: 0.0%
pharmaceuticals
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
Published: 2022-11-10 (Crawled : 14:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -11.03%
H: 5.91%
C: -14.59%
preclinical meeting
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -7.89%
H: 0.0%
C: 0.0%
nyx-783 treatment opioid grant
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Published: 2022-10-18 (Crawled : 12:20) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -0.79%
H: 3.33%
C: 2.23%
report financial results
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
Published: 2022-08-25 (Crawled : 12:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.98%
H: 5.1%
C: 1.31%
nyx-458 dementia disease study phase 2
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
Published: 2022-08-12 (Crawled : 12:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -39.71%
H: 0.0%
C: 0.0%
nyx-2925 fibromyalgia results study phase 2b
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
Published: 2022-08-04 (Crawled : 22:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 7.14%
H: 2.57%
C: -3.75%
results
Global Chemotherapy Induced Peripheral Neuropathy Market to Reach $1.17 Billion by 2028 at a CAGR of 5.4%
Published: 2022-07-15 (Crawled : 16:00) - prnewswire.com
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 6.74%
H: 0.0%
C: -2.56%
global market
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
Published: 2022-07-15 (Crawled : 13:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 6.74%
H: 0.0%
C: -2.56%
report results
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
Published: 2022-06-22 (Crawled : 12:20) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -0.02%
H: 15.24%
C: 1.9%
conference health
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
Published: 2022-05-17 (Crawled : 12:20) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -8.47%
H: 6.42%
C: 3.1%
nyx-783 preclinical presentation pre-clinical
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting
Published: 2022-04-29 (Crawled : 12:20) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 1.09%
H: 1.88%
C: -5.09%
nyx-783 preclinical pre-clinical
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Published: 2022-04-27 (Crawled : 12:00) - biospace.com/
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -3.01%
H: 6.17%
C: -1.11%
report results
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.